48.35 USD
-0.12 (-0.25%)
48.35 USD
0 (0%)
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 191 industry peers in the Pharmaceuticals industry. While SNY has a great profitability rating, there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
In the past year SNY had a positive cash flow from operations.
SNY had positive earnings in each of the past 5 years.
SNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SNY (11.05%) is better than 92.15% of its industry peers.
SNY has a better Return On Equity (19.73%) than 90.05% of its industry peers.
SNY has a better Return On Invested Capital (13.84%) than 93.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 12.85%.
The 3 year average ROIC (7.31%) for SNY is below the current ROIC(13.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY's Profit Margin of 20.35% is amongst the best of the industry. SNY outperforms 91.10% of its industry peers.
In the last couple of years the Profit Margin of SNY has grown nicely.
With an excellent Operating Margin value of 23.59%, SNY belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
The Gross Margin of SNY (71.70%) is better than 78.53% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
SNY has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for SNY remains at a similar level compared to 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
SNY has a Debt to FCF ratio of 2.21. This is amongst the best in the industry. SNY outperforms 93.19% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SNY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.21, SNY is in line with its industry, outperforming 44.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.36%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
With a Current ratio value of 1.27, SNY is not doing good in the industry: 78.01% of the companies in the same industry are doing better.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.94, SNY is doing worse than 79.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -5.35% in the last year.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 2.56% in the last year.
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 7.11% on average per year.
The Revenue is expected to grow by 4.55% on average over the next years.
EPS Next Y2.37%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
EPS Next 5Y7.11%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.55%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.77, the valuation of SNY can be described as reasonable.
Based on the Price/Earnings ratio, SNY is valued cheaper than 90.05% of the companies in the same industry.
SNY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.84.
The Price/Forward Earnings ratio is 9.62, which indicates a very decent valuation of SNY.
Based on the Price/Forward Earnings ratio, SNY is valued cheaper than 87.43% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (23.40), we can say SNY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.77 | ||
| Fwd PE | 9.62 |
4.2 Price Multiples
97.91% of the companies in the same industry are more expensive than SNY, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 91.10% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.89 | ||
| EV/EBITDA | 5.45 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)4.54
PEG (5Y)2.11
EPS Next 2Y5.23%
EPS Next 3Y5.91%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.68%, SNY has a reasonable but not impressive dividend return.
SNY's Dividend Yield is rather good when compared to the industry average which is at 0.61. SNY pays more dividend than 94.76% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, SNY pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.68% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
SNY has decreased its dividend in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
48.35
-0.12 (-0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.31%
Inst Owner Change-5.34%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap117.44B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target62.25 (28.75%)
Short Float %0.29%
Short Ratio2.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.68% |
Yearly Dividend2.24
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-1.46%
PT rev (3m)-3.94%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-4.38%
EPS NY rev (1m)-0.68%
EPS NY rev (3m)-1.93%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)-0.62%
Revenue NY rev (3m)0.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.77 | ||
| Fwd PE | 9.62 | ||
| P/S | 1.47 | ||
| P/FCF | 9.89 | ||
| P/OCF | 8.76 | ||
| P/B | 1.42 | ||
| P/tB | 10.72 | ||
| EV/EBITDA | 5.45 |
EPS(TTM)4.49
EY9.29%
EPS(NY)5.03
Fwd EY10.4%
FCF(TTM)4.89
FCFY10.11%
OCF(TTM)5.52
OCFY11.42%
SpS32.95
BVpS33.97
TBVpS4.51
PEG (NY)4.54
PEG (5Y)2.11
Graham Number58.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.36%
ROIC/WACC1.88
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y2.37%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
EPS Next 5Y7.11%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.55%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.1%
EBIT Next 3Y13.19%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.77 and the Price/Book (PB) ratio is 1.42.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.